Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model

Inadequate Response ◽

PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA™) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

Value in Health ◽

10.1016/s1098-3015(10)72617-6 ◽

2010 ◽

Vol 13 (3) ◽

pp. A128

Author(s):

D Zou ◽

O Desjardins ◽

N Tsao ◽

R Goeree

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Active Rheumatoid Arthritis ◽

Inadequate Response ◽

PBI7 Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany

Value in Health ◽

10.1016/j.jval.2021.04.078 ◽

2021 ◽

Vol 24 ◽

pp. S15

Author(s):

J. Porter ◽

P. Stuart ◽

R. Bartsch ◽

A. Lebioda

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Treatment Initiation ◽

Biologic Treatment ◽

PMS44 - COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT

Value in Health ◽

10.1016/j.jval.2018.09.1758 ◽

2018 ◽

Vol 21 ◽

pp. S295

Author(s):

E. Öksüz ◽

S. Malhan ◽

L. Yanik ◽

E. Koc ◽

E. Erdogan-Ciftci ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Rheumatoid Arthritis Treatment ◽

PMS17 COST EFFECTIVENESS ANALYSIS OF UPADACITINIB AND METHOTREXATE FOR PATIENTS WITH METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS

Value in Health ◽

10.1016/j.jval.2020.04.704 ◽

2020 ◽

Vol 23 ◽

pp. S217

Author(s):

S. Jadhav ◽

Y. Yang

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Cost-effectiveness analysis of endometrial injury on frozen-thawed blastocyst transfer for assisted reproductive technology: a Markov model analysis

Fertility and Sterility ◽

10.1016/j.fertnstert.2018.07.1025 ◽

2018 ◽

Vol 110 (4) ◽

pp. e367

Author(s):

M. Funabiki ◽

S. Taguchi ◽

N. Amano ◽

Y. Nakamura

Keyword(s):

Cost Effectiveness ◽

Markov Model ◽

Assisted Reproductive Technology ◽

Model Analysis ◽

Reproductive Technology ◽

Blastocyst Transfer ◽

Endometrial Injury ◽

Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1834384 ◽

2020 ◽

pp. 1-10

Author(s):

Behzad Fatemi ◽

Soheila Rezaei ◽

Saeed Taheri ◽

Farzad Peiravian

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Active Rheumatoid Arthritis ◽

Breast cancer screening programme in China: does one size fit all? A cost-effectiveness analysis based on a Markov model

The Lancet ◽

10.1016/s0140-6736(18)32631-x ◽

2018 ◽

Vol 392 ◽

pp. S2 ◽

Cited By ~ 1

Author(s):

Li Sun ◽

Rosa Legood ◽

Zia Sadique ◽

Isabel dos-Santos-Silva ◽

Li Yang

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Screening ◽

Markov Model ◽

Breast Cancer Screening ◽

Screening Programme ◽

Effectiveness Analysis ◽

Breast Cancer Screening Programme ◽

Cancer Screening Programme

Cost-Effectiveness Analysis Of Etanercept Versus Available Anti-Tnf And Il-6 Blockers For Treating Rheumatoid Arthritis In El Salvador

Value in Health ◽

10.1016/j.jval.2013.03.1138 ◽

2013 ◽

Vol 16 (3) ◽

pp. A224

Author(s):

M.A. Lutz ◽

R. Zelaya ◽

J.P. Bogantes ◽

G. Cuesta

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

El Salvador ◽

PMS22 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

Value in Health ◽

10.1016/j.jval.2011.02.707 ◽

2011 ◽

Vol 14 (3) ◽

pp. A127

Author(s):

J. Vargas-Valencia ◽

M. Sotelo-Guzmán ◽

J.F. Mould-Quevedo ◽

E. Muciño-Ortega ◽

R.M. Galindo-Suarez

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Cost-Effectiveness Analysis Of Etanercept Versus Available Anti-Tnf And Il-6 Blockers For Treating Rheumatoid Arthritis In Costa Rica

Value in Health ◽

10.1016/j.jval.2013.03.1137 ◽

2013 ◽

Vol 16 (3) ◽

pp. A224

Author(s):

M.A. Lutz ◽

J.P. Bogantes ◽

G. Cuesta ◽

R. Saenz

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Costa Rica ◽